DiscoverTriloTalkEpisode 28: Exploring the Past, Present and Future of Orphan Drugs
Episode 28: Exploring the Past, Present and Future of Orphan Drugs

Episode 28: Exploring the Past, Present and Future of Orphan Drugs

Update: 2024-12-11
Share

Description

Long time friends and industry colleagues, Lisa Chamberlain James with Trilogy and Cheryl Roberts with BioMarin Pharmaceutical sit down to discuss orphan drugs. They go over clinical trial hurdles, key incentives for health authorities, the medical writing process and start with an important question – why are orphan drugs called orphan drugs? Find out on episode 28 of TriloTalk!  

Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Episode 28: Exploring the Past, Present and Future of Orphan Drugs

Episode 28: Exploring the Past, Present and Future of Orphan Drugs

Trilogy Writing & Consulting